Management Change/Compensation (Form 8-K)

On May 17, 2026, Brett Wall, a class II director of the Board of Directors (the "Board") of MiniMed Group, Inc. ("MiniMed") and member of the Board's Nominating and Corporate Governance Committee, notified the Board that he will resign from the Board effective July 3, 2026. His decision to resign is not the result of any disagreement with management or the Board related to MiniMed's operations, policies, or practices. His decision to resign results from his departure as Executive Vice President and President, Neuroscience Portfolio, of Medtronic plc ("Medtronic"), the parent company of MiniMed, which nominated Mr. Wall as a member of the Board.

On May 18, 2026, Scott Cundy was appointed to serve as a director of the Board, effective July 3, 2026, to fill the vacancy resulting from Mr. Wall's departure. Mr. Cundy will serve as class II director whose term expires at the 2027 annual meeting of stockholders and will be a member of the Board's Nominating and Corporate Governance Committee.

Mr. Cundy currently serves as Senior Vice President and Chief Quality, Development, and Innovation Officer at Medtronic, leads the Global Quality, Product Development, and Innovation functions at Medtronic and is a member of the Medtronic Executive Committee. Mr. Cundy also oversees the Medtronic Engineering and Innovation Center. Prior to joining Medtronic in 2023, Mr. Cundy served as Vice President Quality, Regulatory, & Clinical Affairs Diagnostics and Life Sciences Platforms at Danaher Corporation. Mr. Cundy holds a B.S. in Industrial Engineering from Georgia Institute of Technology and an MBA from the University of Minnesota's Carlson School of Management.

Mr. Cundy does not have a material interest in any transaction that is required to be disclosed under Item 404(a) of Regulation S-K, and there is no arrangement or understanding pursuant to which he was selected as a director of the Board.

For so long as Medtronic is an affiliate of MiniMed, Mr. Cundy, as an employee of Medtronic, will receive no compensation for his service on the Board. Thereafter, Mr. Cundy's compensation for service as a director will be consistent with the compensation paid to other non-employee directors of MiniMed as described in MiniMed's Form 8-K filed with the Securities and Exchange Commission on March 9, 2026.